EW
41
-2
DAL
44
-13
PFE
33
-6
GWW
74
7
WEC
75
-2
JWN
53
-2
PLD
40
-3
INTU
65
-4
CI
66
-7
NEM
57
-3
HRB
65
5
DG
25
-6
PNW
63
-3
BDX
27
-23
D
32
4
MUR
31
4
O
30
-9
ADSK
56
-3
PSX
35
-4
HP
25
3
EW
41
-2
DAL
44
-13
PFE
33
-6
GWW
74
7
WEC
75
-2
JWN
53
-2
PLD
40
-3
INTU
65
-4
CI
66
-7
NEM
57
-3
HRB
65
5
DG
25
-6
PNW
63
-3
BDX
27
-23
D
32
4
MUR
31
4
O
30
-9
ADSK
56
-3
PSX
35
-4
HP
25
3
Financhill
Back

Cartesian Therapeutics 10K Form

Sell
40

RNAC
Cartesian Therapeutics

Last Price:
$12.72
Seasonality Move:
13.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RNAC News And Ratings

See the #1 stock for the next 7 days that we like better than RNAC

RNAC Financial Statistics

Sales & Book Value

Annual Sales: $38.9M
Cash Flow: $-7.7M
Price / Cash Flow: 0
Annual Sales: $-0.26
Price / Book: 568.21

Profitability

EPS (TTM): -10.97000
Net Income (TTM): $-77.4M
Gross Margin: --
Return on Equity: 0%
Return on Assets: -20.72%

Cartesian Therapeutics Earnings Forecast

Key Cartesian Therapeutics Financial Ratios

  • The Research & Development expenses have been 115.91% of Revenue.
  • The Net Earning history of RNAC is -198.97% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 7 years.

Cartesian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RNAC
Website: cartesiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.43
Quick Ratio: 9.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RNAC Technical Analysis vs Fundamental Analysis

Sell
40
Cartesian Therapeutics (RNAC) is a Sell

Is Cartesian Therapeutics a Buy or a Sell?